Abstract
Forty patients have been treated for two months with fluspirilene, a new injectable diphenylbutylpiperidine administered intramuscularly once per week. Chronic cases improved satisfactorily and acute cases did rather better, particularly in relation to delusions.
When the average dose was low (5.4 mg) extra-pyramidal effects were uncommon, but if 12 mg was given, more side-effects were encountered. Two patients on fluspirilene 4 mg weekly had dystonic reactions.
If marked hypertension was present, the systolic pressure fell by about 60 mm Hg.
Get full access to this article
View all access options for this article.
